The Gaming of Pharmaceutical Patents Brief Overview.

Slides:



Advertisements
Similar presentations
GATT AND TRIPS.
Advertisements

Presented by Richard J. Berman, Partner Arent Fox LLP Washington, DC
Negotiating Technology License Agreements Tamara Nanayakkara.
Selling Foreign products and services into saudi arabia
Consumer Promotions Chapter 11 with Duane Weaver.
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Recent Developments In Parties Obligations In Hatch-Waxman Act Litigation Brian V. Slater Presented at American Conference Institutes Maximizing Pharmaceutical.
Pharma Workshop IV Patent Linkage in the USA Lawrence T. Welch Eli Lilly and Company.
Adjust your Speaker to Hear Audio Narration Monetizing Your Patents Ten Techniques for Turning Patents into Profits.
Damages Calculations in Infringement Cases Frank S. Farrell F.S. Farrell, LLC 7101 York Ave., So.; Suite 305 Edina, MN Phone: (952) Fax:
Mylan Laboratories Inc. (MYL) Solomon Lee, Analyst Graduation Date: April 2008.
Patent settlements in the EU EGA perspective Ingrid Vandenborre 18 October 2013.
Exclusivity And FDA Barriers To Market Entry In The US Brian V. Slater, Esq. Fitzpatrick, Cella, Harper & Scinto Pharmaceutical.
An Introduction to the Hatch-Waxman Act and ANDA Litigation
FDA Counsel.com 1 ANDAs, OTCs, Orphans and Cosmetics -- Key Issues Wednesday, August 18, 2004 SDRAN RAC STUDY COURSE Michael A. Swit, Esq. FDACounsel.com.
A rose (cartel) by any other name? – The economics of pay-for-delay settlements Mat Hughes – November
What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
Hatch Waxman: Prescriptions for Innovative and Inexpensive Medicines
1 Law School For Pharmaceutical And Medical Manufacturer Executives Understanding Your Company’s Antitrust Exposure While Litigating Or Settling Patent.
Hatch-Waxman Litigation and Reverse-Payment Settlements Anastasia P. Winslow Senior Counsel, Patents - Bristol-Myers Squibb Company.
Hatch-Waxman Reforms Under The “Medicare Prescription Drug, Improvement, And Modernization Act 2003” Brian V. Slater, Esq. Fitzpatrick,
The Hatch-Waxman Act and How it Works: Balancing Incentives to Innovate with the Need for Affordable Drugs Minnesota Intellectual Property Association.
State Antitrust Enforcement in the Pharmaceutical Industry
Potential Impact on Data Exclusivity: A Necessary Form of IP in a FOB World Susan Finston, President “Biosimilars and Follow-On Biologics” Doubletree Hotel,
Hatch-Waxman: Upsetting the Balance Tim Gilbert. Hatch-Waxman: A Delicate Balance InnovationAccess.
ANDAs – Key Regulatory and Legislative Issues June 4, 2003 Annual OCRA/FDA Education Conference Irvine, California Michael A. Swit, Esq. Law Offices of.
Prof. David W. Opderbeck Seton Hall University Law School Gibbons Institute of Law, Science & Technology.
A Problem At the Patent-Regulatory-Antitrust Interface: Settling Hatch-Waxman Patent Infringement Cases by Reverse Payments Fordham Intellectual Property.
Patent Term Adjustments and Extensions
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
Leveraging Pharmaceutical Patent Exclusivities Michael R. Dzwonczyk Sughrue Mion, PLLC Global Perspective on Pharma and Biotech Patents Taj Residency,
Legal and Regulatory Considerations When Pursuing an ANDA Shaoyu Chen Managing Director China Food and Drug Practice Covington & Burling LLP Third DIA.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.
© 2009 Pharmaceutical Law Group PC Market Exclusivity Paradigm Gregory J. Glover, MD, JD Pharmaceutical Law Group
Authorized Generics: Good For Everyone (Even Generics) Jerome A. Swindell Senior Counsel.
AIPLA IP Practice in Japan Committee Pre-Meeting Joerg-Uwe Szipl Griffin and Szipl, PC and Ranga Sourirajan McKool Smith, P.C. October 13, 2009 Are Reverse.
Protecting Intellectual Property Around The World 6 th Annual The Security Summit Mitchell P. Brook Partner, Luce Forward
H I R S C H & P A R T N E R S A v o c a t S o l i c i t o r R e c h t s a n w a l t Pharmaceutical settlement agreements and competition law A litigation.
Industry Analysis. t All companies face competition. © For resources, customers, sales revenues, and profits. t All companies face uncertain industry.
DAVID HARDING MARCH 12, 2008 DCAT WEEK PERCEPTIONS vs. REALITY Facts and Figures on the Generic Industry.
(c) 2007 Renita Rathinam Authorized Generics Practice and the Battle Over Generic Exclusivity in the U.S. Market Renita S. Rathinam
The FTC, Pharmaceuticals, Antitrust & IP: A Grab Bag October 23, 2008 This presentation was prepared from public sources. The views expressed herein do.
Medicines Differentiation Analysis MyCore 18 January 2011.
© 2008 Dechert LLP Pharma v. Pharma or Pharma & Pharma: The Legal Interface Between the Makers of Original and Copied Versions of Medicines AIPLA Antitrust,
Antitrust in the Pharmaceutical Industry: An Introduction to Brand-Generic Competition Scott Hemphill New York State Office of the Attorney General George.
Our PatientsOur PeopleOur BusinessOur Community © 2008 Endo Pharmaceuticals. All Rights Reserved. Biosimilars 2009 Update Pending Legislation Review Pam.
Our PatientsOur PeopleOur BusinessOur Community © 2008 Endo Pharmaceuticals. All Rights Reserved. Strategies to Maximize Patent Term Balancing Scope and.
Biotechnology Chemical Pharmaceutical Customer Partnership
1 Business-Level Strategy. 2 Business-level strategy: an integrated and coordinated set of commitments and actions the firm uses to gain a competitive.
Hatch-Waxman As Amended (MMA) Thomas O. Henteleff Kleinfeld, Kaplan and Becker, LLP November 9, 2005.
CDER/Office of Generic Drugs1 Regulatory Issues Related to Crystal Habits - Polymorphism 1:45 - 2:00Polymorphs - What’s the Problem? Gary Buehler, R. Ph.,
 An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate.
Intellectual Property Management: Stories of Successful Strategies Srividhya Ragavan Professor of Law University of Oklahoma Law Center.
Patent settlements for medicines -- status under EU and US antitrust law -- Luc Gyselen, Partner Arnold & Porter LLP Brussels Symposium on the Interface.
BARASH LAW LLC Case Competition Eyal H. Barash BARASH LAW LLC January 29, 2016
Recent FTC Pharmaceutical Cases: Background and Examples Sue H. Kim This presentation was prepared from public sources. The views expressed herein do not.
Emerging Health Care Issues: The U.S. FTC Report on Follow-on Biologic Drug Competition Sue H. Kim Foreign Attorney Yoon & Yang LLC.
PTAB Litigation 2016 Part 11 – Bio/Pharma Issues 1.
Patent Settlements, Risk, and Competition Mark R. Patterson Fordham University School of Law Patent Settlements: The Issues Beyond the “Reverse Payment”
Cheaper Drugs Today And Better Drugs Tomorrow History The industry’s lobbying efforts were well-timed. In the late 1970s, the U.S. economy was in recession.
Hatch-Waxman Overview
Biotechnology Chemical Pharmaceutical Customer Partnership
Class 21 Antitrust, Winter, 2018 Antitrust and Patents
Finding and Understanding Patents
Pharma Workshop IV Patent Linkage in the USA
The 8th Annual Pharmaceutical Regulatory & Compliance Congress
Global Business & Legal Issues
Finding and Understanding Patents
Presentation transcript:

The Gaming of Pharmaceutical Patents Brief Overview

Hatch-Waxman Act Hatch-Waxman was designed to speed entry of generic drugs to compete with patented pharmaceuticals The results of the act seek to balance the interests of the branded manufacturers with those of generics The reality has been that as branded manufacturers learned how to “change the game”, they gained an advantage in keeping generics out Average time keeping generics out increased from 9 to 11.5 years

The Mechanics of Hatch-Waxman Branded manufacturer files a New Drug Application (NDA) to market branded pharmaceutical There’s an automatic five-year exclusivity period for a successful NDA Successful NDA listed in the FDA “Orange Book”

Hatch-Waxman: Enter the Generics Generics seek to “engineer around” the branded patent. They file a less expensive ANDA asserting bioequivalence In the interesting case, this is a “Paragraph IV Certification” invalidity or non-infringement of branded patent This triggers an automatic 30-month stay while litigation occurs. If successful, the first to file an ANDA has a 180 exclusivity period.

Branded Strategy: Hoechst-Andrx Andrx is first to file a Paragraph IV ANDA for a generic bioequivalent to Hoechst’s popular drug Cardizem Hoechst sues alleging infringement and the suit is settled as follows The Settlement Andrx agrees not to market its generic for at least 18 months after the 30 month stay expires Andrx is paid $40 million/year to stay off in the event it loses the suit and $60 million/year if it wins Andrx agreed to retain the 180 day exclusivity

Questions: Why would Hoechst do this? How is the agreement structured to take advantage of the Hatch-Waxman game?.

More Tactics: Many Orange Book Filings In response to the FTC, branded manufacturers have evolved new strategies Successive Orange Book filings Settlements of non-infringement as opposed to invalidity Why might this be useful?

Take Aways The 180 day exclusivity provides leverage for the branded manufacturer to block multiple generics while negotiating with only one The 30 month stay allows for creative delaying tactics By negotiating to delay the entry of the first filer, the brand effectively delays entry by all filers Thinking strategically pays: Clever strategies by brands in the legal environment of Hatch-Waxman have unambiguously increased their profitability.